Shuttle Pharmaceuticals Holdings Inc (SHPH)

$3.26 -0.06 (-1.81%)
Market Cap 1.46M
Revenue (ttm) 0.00
Net Income (ttm) -9.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 157,500
Avg Vol 274,586
Day's Range N/A - N/A
Shares Out 10.98M
Stochastic %K 8%
Beta -1.10
Analysts Strong Buy
Price Target N/A

Company Profile

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HD...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 403 4212
Address:
401 Professional Drive, Suite 260, Gaithersburg, United States
Charliemuscle
Charliemuscle Jun. 17 at 1:38 AM
$SHPH still not compliant... Offering is needed to meet the $5 million valuation
2 · Reply
chapelp
chapelp Jun. 16 at 11:19 PM
$SHPH Zero f@king available shares to short and THEY keep shorting!!! Scam in cohort with MM and protected by SEC
1 · Reply
chapelp
chapelp Jun. 16 at 11:12 PM
$SHPH this POS will slowly go to $1 and under
0 · Reply
Maxim_Trader
Maxim_Trader Jun. 16 at 10:35 PM
$SHPH Can’t wait to see what kind of PR comes next 🎰
1 · Reply
Mithra1
Mithra1 Jun. 16 at 10:32 PM
$SHPH Is this dead?
0 · Reply
TwongStocks
TwongStocks Jun. 16 at 8:42 PM
Today's RS results, part 1: $SMX 1 for 4.1 Previous close $.9297, $3.81177 split-adjusted Today's close $3.60 🔴Down 5.56% $JFBR 1 for 17 Previous close $0.2908, $4.9436 split-adjusted Today's close $5.60 🟢Up 13.28% $SHPH 1 for 25 Previous close $0.1328, $3.32 split-adjusted Today's close $3.26 🔴Down 1.80% $JZ 1 for 10 Previous close $0.2614, $2.614 split-adjusted Today's close $2.86 🟢Up 9.41%
0 · Reply
Mithra1
Mithra1 Jun. 16 at 7:28 PM
$SHPH Why does it show market cap is 36.2 million? SHPH
0 · Reply
Ruttobillions
Ruttobillions Jun. 16 at 6:29 PM
$SHPH 240K float. Tiny news and the baby is flying to 10 in record 30 minutes! On another note, the company is trash and may spiral to another R/S in couple of months. I think it will pump one massively before going south!
1 · Reply
AnnaKan
AnnaKan Jun. 16 at 3:32 PM
$SHPH reverse split 25-1 effective today float now 377k $RGC forward split 38-1 effective today also ! Both splits looking good worth a watch ! GL 💚
0 · Reply
UnicornPicks
UnicornPicks Jun. 16 at 2:40 PM
Some ideas this morning but quiet..$BATL $JBFR $SHPH $ZDGE
0 · Reply
Latest News on SHPH
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Jun 12, 2025, 12:00 PM EDT - 4 days ago

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Jun 12, 2025, 8:30 AM EDT - 4 days ago

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Jun 4, 2025, 4:01 PM EDT - 12 days ago

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Provides Corporate Update

May 15, 2025, 4:45 PM EDT - 4 weeks ago

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

May 8, 2025, 4:01 PM EDT - 5 weeks ago

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Apr 21, 2025, 4:15 PM EDT - 2 months ago

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Apr 10, 2025, 4:01 PM EDT - 2 months ago

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Mar 13, 2025, 4:10 PM EDT - 3 months ago

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Mar 12, 2025, 9:24 AM EDT - 3 months ago

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Mar 12, 2025, 6:20 AM EDT - 3 months ago

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Feb 26, 2025, 10:45 AM EST - 3 months ago

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 7, 2025, 9:00 AM EST - 5 months ago

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Nov 26, 2024, 9:00 AM EST - 7 months ago

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Nov 13, 2024, 5:00 PM EST - 7 months ago

Shuttle Pharma Provides Third Quarter 2024 Corporate Update

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Oct 29, 2024, 9:05 PM EDT - 8 months ago

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Oct 28, 2024, 4:05 PM EDT - 8 months ago

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Sep 16, 2024, 9:00 AM EDT - 9 months ago

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Sep 4, 2024, 4:15 PM EDT - 10 months ago

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Aug 26, 2024, 4:10 PM EDT - 10 months ago

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Aug 14, 2024, 4:10 PM EDT - 10 months ago

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Jul 19, 2024, 9:00 AM EDT - 11 months ago

Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Jun 18, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 22, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Shuttle Pharma Provides First Quarter 2024 Corporate Update

May 14, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23, 2024, 4:15 PM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Mar 22, 2024, 9:00 AM EDT - 1 year ago

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Mar 5, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13, 2024, 8:00 AM EST - 1 year ago

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Jan 23, 2024, 4:30 PM EST - 1 year ago

Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8, 2024, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023, 9:00 AM EST - 1 year ago

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 31, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 25, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Sep 13, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer & Men's Health Fair

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Sep 11, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

Aug 29, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Aug 15, 2023, 9:00 AM EDT - 1 year ago

Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Aug 3, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

May 26, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

May 17, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

Mar 22, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

Mar 15, 2023, 9:00 AM EDT - 2 years ago

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

Mar 9, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

Feb 23, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

Jan 26, 2023, 4:15 PM EST - 2 years ago

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

Jan 17, 2023, 9:00 AM EST - 2 years ago

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023

Charliemuscle
Charliemuscle Jun. 17 at 1:38 AM
$SHPH still not compliant... Offering is needed to meet the $5 million valuation
2 · Reply
chapelp
chapelp Jun. 16 at 11:19 PM
$SHPH Zero f@king available shares to short and THEY keep shorting!!! Scam in cohort with MM and protected by SEC
1 · Reply
chapelp
chapelp Jun. 16 at 11:12 PM
$SHPH this POS will slowly go to $1 and under
0 · Reply
Maxim_Trader
Maxim_Trader Jun. 16 at 10:35 PM
$SHPH Can’t wait to see what kind of PR comes next 🎰
1 · Reply
Mithra1
Mithra1 Jun. 16 at 10:32 PM
$SHPH Is this dead?
0 · Reply
TwongStocks
TwongStocks Jun. 16 at 8:42 PM
Today's RS results, part 1: $SMX 1 for 4.1 Previous close $.9297, $3.81177 split-adjusted Today's close $3.60 🔴Down 5.56% $JFBR 1 for 17 Previous close $0.2908, $4.9436 split-adjusted Today's close $5.60 🟢Up 13.28% $SHPH 1 for 25 Previous close $0.1328, $3.32 split-adjusted Today's close $3.26 🔴Down 1.80% $JZ 1 for 10 Previous close $0.2614, $2.614 split-adjusted Today's close $2.86 🟢Up 9.41%
0 · Reply
Mithra1
Mithra1 Jun. 16 at 7:28 PM
$SHPH Why does it show market cap is 36.2 million? SHPH
0 · Reply
Ruttobillions
Ruttobillions Jun. 16 at 6:29 PM
$SHPH 240K float. Tiny news and the baby is flying to 10 in record 30 minutes! On another note, the company is trash and may spiral to another R/S in couple of months. I think it will pump one massively before going south!
1 · Reply
AnnaKan
AnnaKan Jun. 16 at 3:32 PM
$SHPH reverse split 25-1 effective today float now 377k $RGC forward split 38-1 effective today also ! Both splits looking good worth a watch ! GL 💚
0 · Reply
UnicornPicks
UnicornPicks Jun. 16 at 2:40 PM
Some ideas this morning but quiet..$BATL $JBFR $SHPH $ZDGE
0 · Reply
chapelp
chapelp Jun. 16 at 1:52 PM
$SHPH now would be a good time for a decent PR
1 · Reply
Diggersen
Diggersen Jun. 16 at 1:46 PM
$SHPH from NOW ON ! LOW FLOATER ! 1 mio shares in da float ! this cann go epic
0 · Reply
Diggersen
Diggersen Jun. 16 at 1:42 PM
$SHPH with such LOW FLOAT ! this will go EPIC ! soon. any opinions?
1 · Reply
TwongStocks
TwongStocks Jun. 16 at 12:32 PM
All seven NASDAQ companies with a RS are being unhalted at 9:00am ET. $SMX 1 for 4.1. Will reduce outstanding shares from approx 4m to approx 1m. $JFBR 1 for 17. Will reduce outstanding shares from approx 9,407,534 to approx 553,385. $SHPH 1 for 25. Will reduce outstanding shares from approx 26,210,037 to approx 1,048,401. $JZ 1 for 10. Will reduce the number of outstanding ADSs from 7,716,666 to approx 771,666.
0 · Reply
Diggersen
Diggersen Jun. 16 at 8:18 AM
$SHPH mcap just 1 mio usd ! -> this can fly with good news ! or RM
0 · Reply
Kevin73ca
Kevin73ca Jun. 16 at 12:33 AM
$GCTK $JFBR $JZ $SHPH $SMX
0 · Reply
jerry_springer
jerry_springer Jun. 15 at 10:11 PM
$GCTK $JFBR $JZ $SHPH $SMX
1 · Reply
makedatbread88
makedatbread88 Jun. 15 at 9:49 PM
Watching these reverse split low float plays $SMX 1 for 4.1. Will reduce outstanding shares from approx 4m to approx 1m. $JFBR 1 for 17. Will reduce outstanding shares from approx 9,407,534 to approx 553,385. $SHPH 1 for 25. Will reduce outstanding shares from approx 26,210,037 to approx 1,048,401. $JZ 1 for 10. Will reduce the number of outstanding ADSs from 7,716,666 to approx 771,666. $GCTK 1 for 60. Will reduce outstanding shares from approx 32,541,327 to approx 542,356.
0 · Reply
tommy_john
tommy_john Jun. 15 at 5:52 PM
$SHPH ready for this. Chart is nice! $JFBR another split
0 · Reply
Mithra1
Mithra1 Jun. 14 at 6:09 AM
$SHPH And now this ticker forum is dead.
2 · Reply
Mithra1
Mithra1 Jun. 14 at 1:09 AM
$SHPH Can this run to $10 on Monday after the R/S brings it to roughly 3.50 in the 25-1 split.
0 · Reply
Mithra1
Mithra1 Jun. 14 at 12:00 AM
$SHPH Trading halt. I suspect that is because the Reverse Split will take effect Monday morning. Thoughts?
1 · Reply